MedKoo product information:

  CPX-351

Description of CPX-351: CPX-351 Liposome Injection is a liposomal formulation of a synergistic 5:1 molar ratio of cytarabine and daunorubicin, two agents commonly used to treat hematologic malignancies, particularly acute myeloid leukemia (AML). Research at Celator has shown that cytarabine:daunorubicin administered in a 5:1 ratio delivers a synergistic benefit. Further research has shown that this combination of chemotherapeutic drugs delivered in other ratios can be antagonistic. A Phase 1 dose escalation study in 48 patients with advanced leukemia (45 patients with AML and 3 patients with ALL) has been completed with CPX-351. Data from this study was presented at the 2008 American Society of Hematology meeting. Based on the safety and efficacy seen in the Phase 1 study, Celator has initiated two randomized Phase 2 studies.  (source: http://www.celatorpharma.com/new/products_cpx351.html).

Current developer:    Celator Pharmaceuticals.

1: Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, Chantepie S, Gardin C, Rousselot P, Chevret S, Dombret H, Castaigne S. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association. Am J Hematol. 2011 Sep 26. doi: 10.1002/ajh.22201. [Epub ahead of print] PubMed PMID: 22072535.

2: Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011 Jul;39(7):741-50. Epub 2011 Apr 9. PubMed PMID: 21530609.

3: Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011 Mar 10;29(8):979-85. Epub 2011 Jan 31. PubMed PMID: 21282541.

4: Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, Pautas C, Berthou C, Guyotat D, Cony-Makhoul P, Gardembas M, Michallet M, Hayette S, Cayuela JM, Weiss IR, Réa D, Castaigne S, Mahon FX, Guilhot F, Rousselot P. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res. 2011 Jun;35(6):777-82. Epub 2010 Dec 10. PubMed PMID: 21145590.

5: Lim WS, Tardi PG, Xie X, Fan M, Huang R, Ciofani T, Harasym TO, Mayer LD. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. Leuk Lymphoma. 2010 Aug;51(8):1536-42. PubMed PMID: 20528246.

6: Advani AS, Tiu R, Saunthararajah Y, Maciejewski J, Copelan EA, Sobecks R, Sekeres MA, Bates J, Rush ML, Tripp B, Salvado A, Noon E, Howard M, Jin T, Hsi E, Egorin MJ, Lim K, Cotta CV, Price C, Kalaycio M. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. Leuk Res. 2010 Dec;34(12):1622-6. Epub 2010 Apr 27. PubMed PMID: 20427086.

7: Dicko A, Kwak S, Frazier AA, Mayer LD, Liboiron BD. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int J Pharm. 2010 May 31;391(1-2):248-59. Epub 2010 Feb 13. PubMed PMID: 20156541.

8: Lim WS, Tardi PG, Dos Santos N, Xie X, Fan M, Liboiron BD, Huang X, Harasym TO, Bermudes D, Mayer LD. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010 Sep;34(9):1214-23. Epub 2010 Feb 6. PubMed PMID: 20138667.

9: Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen IM, Willman CL, Kopecky KJ, Appelbaum FR. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2010 Jan;148(1):48-58. Epub 2009 Oct 11. PubMed PMID: 19821823; PubMed Central PMCID: PMC2967366.

10: Schittenhelm MM, Kampa KM, Yee KW, Heinrich MC. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle. 2009 Aug 15;8(16):2621-30. Epub 2009 Aug 24. PubMed PMID: 19625780.

11: Lech-Maranda E, Seweryn M, Giebel S, Holowiecki J, Piatkowska-Jakubas B, Wegrzyn J, Skotnicki A, Kielbinski M, Kuliczkowski K, Paluszewska M, Jedrzejczak WW, Dutka M, Hellmann A, Flont M, Zdziarska B, Palynyczko G, Konopka L, Szpila T, Gawronski K, Sulek K, Sokolowski J, Kloczko J, Warzocha K, Robak T. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). Int J Infect Dis. 2010 Feb;14(2):e132-40. Epub 2009 Jul 5. PubMed PMID: 19581118.

12: Morris KL, Adams JA, Liu Yin JA. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin. Leuk Res. 2009 Aug;33(8):1096-9. Epub 2009 Mar 5. PubMed PMID: 19268363.

13: Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res. 2009 Aug;33(8):1055-61. Epub 2008 Dec 23. PubMed PMID: 19108889.

14: Bayne WF, Mayer LD, Swenson CE. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J Pharm Sci. 2009 Jul;98(7):2540-8. PubMed PMID: 19009594.

15: Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Ann Hematol. 2009 Feb;88(2):151-8. Epub 2008 Aug 16. PubMed PMID: 18709502.

16: Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, Harvie P, Bermudes D, Mayer L. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009 Jan;33(1):129-39. Epub 2008 Aug 3. PubMed PMID: 18676016.

17: Sitar DS, Aoki FY, Bow EJ. Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine. J Clin Pharmacol. 2008 Aug;48(8):995-8. Epub 2008 May 21. PubMed PMID: 18495946.

18: Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study. Ann Hematol. 2008 May;87(5):361-7. Epub 2007 Dec 12. PubMed PMID: 18074133.

19: Luo ZG, Zhong L, Chen FY, Wang HR, Ouyang RR. [Effect of daunorubicin and cytarabine on cell line NB4]. Zhonghua Xue Ye Xue Za Zhi. 2007 Apr;28(4):247-9. Chinese. PubMed PMID: 17877202.

20: Candoni A, Michelutti A, Simeone E, Damiani D, Baccarani M, Fanin R. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins. Eur J Haematol. 2006 Oct;77(4):293-9. Epub 2006 Jul 19. PubMed PMID: 16856922.

21: Xu WL, Shen HL, Ao ZF, Chen BA, Xia W, Gao F, Zhang YN. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk Res. 2006 Apr;30(4):407-13. Epub 2005 Oct 10. PubMed PMID: 16219352.

22: van der Holt B, Löwenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, Ossenkoppele GJ, Verhoef GE, Ferrant A, Crump M, Selleslag D, Theobald M, Fey MF, Vellenga E, Dugan M, Sonneveld P. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood. 2005 Oct 15;106(8):2646-54. Epub 2005 Jun 30. PubMed PMID: 15994288.

23: Clavio M, Pierri I, Venturino C, Garrone A, Canepa L, Miglino M, Varaldo R, Ballerini F, Michelis GL, Balocco M, Abdall N, Gatto S, Gobbi M. Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia. Leuk Lymphoma. 2004 Dec;45(12):2527-30. PubMed PMID: 15621773.

24: Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 1;22(21):4290-301. PubMed PMID: 15514371.

25: Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol. 2004 Nov;83(11):696-703. Epub 2004 Aug 18. PubMed PMID: 15322763.

26: Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T, Cherrington JM, Heinrich MC. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood. 2004 Dec 15;104(13):4202-9. Epub 2004 Aug 10. PubMed PMID: 15304385.

27: Gerrard G, Payne E, Baker RJ, Jones DT, Potter M, Prentice HG, Ethell M, McCullough H, Burgess M, Mehta AB, Ganeshaguru K. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica. 2004 Jul;89(7):782-90. PubMed PMID: 15257929.

28: Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K; Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004 May;18(5):989-97. PubMed PMID: 14999298.

29: Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003 Dec 15;21(24):4496-504. PubMed PMID: 14673036.

30: Wiernik PH, Cassileth PA, Leong T, Hoagland HC, Bennett JM, Paietta E, Oken MM; Eastern Cooperative Oncology Group Study. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486). Leuk Lymphoma. 2003 Sep;44(9):1515-21. PubMed PMID: 14565653.

31: Pea F, Russo D, Michieli M, Damiani D, Fanin R, Michelutti A, Michelutti T, Piccolrovazzi S, Baccarani M, Furlanut M. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia. Clin Pharmacokinet. 2003;42(9):851-62. PubMed PMID: 12882589.

32: Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res. 2003 Oct;27(10):887-91. PubMed PMID: 12860007.

33: Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 1;97(7):1711-20. PubMed PMID: 12655528.

34: Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2003 Mar 1;97(5):1234-41. PubMed PMID: 12599230.

35: Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Löfvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L, Tangen JM, Tidefelt U, Udén AM, Paul C, Liliemark J. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk Res. 2003 Apr;27(4):323-8. PubMed PMID: 12531223.

36: Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW, Norwood TH, Chen IM, Balcerzak SP, Johnson DB, Appelbaum FR. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002 Dec 1;100(12):3869-76. Epub 2002 Aug 1. PubMed PMID: 12393614.

37: Sonneveld P, Burnett A, Vossebeld P, Ben-Am M, Rosenkranz G, Pfister C, Verhoef G, Dekker A, Ossenkoppele G, Ferrant C, Yin L, Gratwohl A, Kovacsovics T, Vellenga E, Capdeville R, Löwenberg B. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. Hematol J. 2000;1(6):411-21. PubMed PMID: 11920222.

38: Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer. 2001 Jul 1;92(1):7-14. PubMed PMID: 11443603.

39: Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith R, Baer M, Schiffer CA. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. J Clin Oncol. 1999 Sep;17(9):2831-9. PubMed PMID: 10561359.

40: Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R, et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol. 1999 Aug;70(2):97-104. PubMed PMID: 10497848.

41: Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999 Jun 15;93(12):4116-24. PubMed PMID: 10361108.

42: Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998 Mar;16(3):872-81. PubMed PMID: 9508168.

43: Masaoka T, Ogawa M, Yamada K, Kimura K, Ohashi Y. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia. Semin Hematol. 1996 Oct;33(4 Suppl 3):12-7. PubMed PMID: 8916311.

44: Qiau Z, Wang C, Yang L. [Consolidation therapy with high-dose cytarabine and daunorubicin for prolonged disease free survival in acute myelocytic leukemia]. Zhonghua Nei Ke Za Zhi. 1996 Aug;35(8):545-8. Chinese. PubMed PMID: 9594148.

45: Freund DA, Dittus RS. Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpatient resource utilization. J Natl Cancer Inst Monogr. 1995;(19):37-40. PubMed PMID: 7577203.

46: Godwin J. Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study. J Natl Cancer Inst Monogr. 1995;(19):31-5. PubMed PMID: 7577202.

47: Masaoka T, Ogawa M, Yamada K, Kimura K, Ohhashi Y. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group]. Gan To Kagaku Ryoho. 1993 Oct;20(13):1995-2005. Japanese. PubMed PMID: 8215474.

48: Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PL. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992 Jul;10(7):1103-11. PubMed PMID: 1607916.

49: Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios MB, Beran M, Deisseroth A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1992 Mar;10(3):398-405. PubMed PMID: 1740679.

50: Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992 Jan 15;79(2):313-9. PubMed PMID: 1730080.

51: Ohno R, Yokomaku S, Okumura M, Nagai T, Kitaori K, Ito T, Takeo T, Sugiura I, Yano K, Ito Y, et al. Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults. Int J Hematol. 1991 Dec;54(6):487-93. PubMed PMID: 1793832.

52: Ellison RR, Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES, Woliver T, Royston I, Davey FR, Glicksman AS, et al. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol. 1991 Nov;9(11):2002-15. PubMed PMID: 1941059.

53: Ko WS, Chen LM, Hwang SH, Chao TY, Wang CC, Kao WY, Lee WC, Hwang WS. Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine. Zhonghua Yi Xue Za Zhi (Taipei). 1991 Sep;48(3):185-9. PubMed PMID: 1657335.

54: Phillips GL, Reece DE, Shepherd JD, Barnett MJ, Brown RA, Frei-Lahr DA, Klingemann HG, Bolwell BJ, Spinelli JJ, Herzig RH, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood. 1991 Apr 1;77(7):1429-35. PubMed PMID: 2009367.

55: Wahlin A, Hörnsten P, Hedenus M, Malm C. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemother Pharmacol. 1991;28(6):480-3. PubMed PMID: 1934252.

56: Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F, Falconi E, Geraci E, Ladogana S, Latagliata R, et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer. 1991;27(6):750-5. PubMed PMID: 1829918.

57: Champlin R, Gajewski J, Nimer S, Vollset S, Landaw E, Winston D, Schiller G, Ho W. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol. 1990 Jul;8(7):1199-206. PubMed PMID: 1694236.

58: Bär BM, de Witte T, de Pauw BE, Haanen C. Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes. Neth J Med. 1990 Feb;36(1-2):19-24. PubMed PMID: 2314517.

59: Ohno R, Yokomaku S, Okumara M, Tanimoto M, Morishita Y, Morishima Y, Kodera Y, Saito H. Intensive induction therapy with behenoyl, cytosine arabinoside, daunorubicin, and 6-mercaptopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine, and intermediate-dose continuous cytarabine (M-85 protocol) for adult acute myelogenous leukemia. Haematol Blood Transfus. 1990;33:304-8. PubMed PMID: 2182424.

60: Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol. 1989 Sep;7(9):1260-7. PubMed PMID: 2769327.

61: Wiernik PH, Case DC Jr, Periman PO, Arlin ZA, Weitberg AB, Ritch PS, Todd MB. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia. Semin Oncol. 1989 Feb;16(1 Suppl 2):25-9. PubMed PMID: 2928807.

62: Berman E, Arlin ZA, Gaynor J, Miller W, Gee T, Kempin SJ, Mertelsmann R, Andreeff M, Reich L, Nahmias N, et al. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia. 1989 Feb;3(2):115-21. PubMed PMID: 2911205.

63: Linkesch W, Michlmayr G, Gerhartz H, Illinger H, König H, Düllmann J, Keilhauer R, Moldrzyk D. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results. Onkologie. 1989 Feb;12(1):8-10. PubMed PMID: 2654791.

64: Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep. 1987 Dec;71(12):1189-92. PubMed PMID: 3690528.

65: Archimbaud E, Fiere D, Treille-Ritouet D, Adeleine P, Guyotat D, Sebban C, Vuvan H, Viala JJ. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial. Cancer Treat Rep. 1987 Jun;71(6):571-4. PubMed PMID: 3555788.

66: Björkholm M, Killander A. Daunorubicin versus aclarubicin in combination with cytarabine and thioguanine in elderly patients with acute nonlymphocytic leukemia, a preliminary report. Eur J Haematol Suppl. 1987;47:49-54. PubMed PMID: 3471525.

67: Nowrousian MR, Pfeiffer R, Schaefer UW, Osieka R, Niederle N, Anders C, Schmidt CG. Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia. Haematol Blood Transfus. 1987;30:352-5. PubMed PMID: 3305206.

68: Kalwinsky DK, Dahl GV, Mirro J, Jackson CW, Look AT. Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine. Med Pediatr Oncol. 1986;14(5):245-50. PubMed PMID: 2431255.

69: Freund M, Poliwoda H, Bodenstein H, Eisert R. Treatment of acute myelocytic leukemia with a daunorubicin-cytarabine-6 thioguanine regimen without maintenance therapy. Onkologie. 1985 Jun;8(3):150-2. PubMed PMID: 3895097.

70: Pedersen-Bjergaard J, Brincker H, Ellegaard J, Drivsholm A, Freund L, Jensen KB, Jensen MK, Nissen NI. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial. Cancer Treat Rep. 1984 Oct;68(10):1233-8. PubMed PMID: 6597002.

71: Winton EF, Miller D, Vogler WR. Intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine, and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia. Cancer Treat Rep. 1981 May-Jun;65(5-6):389-92. PubMed PMID: 6165470.

72: Fried J, Perez AG, Doblin J, Clarkson BD. Kinetic and cytotoxic effects of cytarabine and daunorubicin on cells in culture. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):153-6. PubMed PMID: 7194735.

73: Kohn D, Flatau E, Daher O, Zuckerman F. Treatment of psoriasis with daunorubicin and cytarabine. Arch Dermatol. 1980 Oct;116(10):1101-2. PubMed PMID: 6932826.

74: Coltman CA Jr, Bodey GP, Hewlett JS, Haut A, Bickers J, Balcerzak SP, Costanzi JJ, Freireich EJ, McCredie KB, Groppe C, Smith TL, Gehan EA. Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicin. Arch Intern Med. 1978 Sep;138(9):1342-8. PubMed PMID: 686922.

75: Rees JK, Hayhoe FG. D.A.T. (daunorubicin, cytarabine, 6-thioguanine) in acute myeloid leukaemia. Lancet. 1978 Jun 24;1(8078):1360-1. PubMed PMID: 78123.